The -1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients

Journal of Psychopharmacology

Volumn 22, Issue 8, 2008, Pages 904-909

  Wang, L ^a,b   Fang, C ^a,b   Zhang, A ^a,b   Du, J ^a,b   Yu, L ^a,b   Ma, J ^a,b   Feng, G ^c   Xing, Q ^a,b   He, L ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

5 HT1A; Pharmacogenomics; Risperidone; Schizophrenia; Treatment response

Indexed keywords

RISPERIDONE; SEROTONIN 1A RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEGATIVE SYNDROME; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT1A; RISPERIDONE; SCHIZOPHRENIA;

EID: 52949103968     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107081522     Document Type: Article

References (32)

1. Bantick R.A., Deakin J.F., Grasby P M. (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37-46
2. Burroughs V.J., Maxey R.W., Levy R.A. (2002) Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 94: 1-26
3. David S.R., Taylor C.C., Kinon B.J., Breier A. (2000 a) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: 1085-1096
4. David S.R., Taylor C.C., Kinon B.J., Breier A. (2000 b) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: 1085-1096
5. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., Artigas F. (2005). Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25: 10831-10843
6. Hashimoto R., Suzuki T., Iwata N., Yamanouchi Y., Kitajima T., Kosuga A., Tatsumi M., Ozaki N., Kamijima K., Kunugi H. (2005) Association study of the frizzled-3 (FZD3) gene with schizophrenia and mood disorders. J Neural Transm 112: 303-307
7. Hong C.J., Chen T.J., Yu Y.W., Tsai S.J. (2006) Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 6: 27-33
8. Ichikawa J., Ishii H., Bonaccorso S., Fowler W. L, O' Laughlin I.A., Meltzer H.Y. (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531
9. Kato N., Sugiyama T., Morita H., Kurihara H., Yamori Y., Yazaki Y. (1998) G protein beta3 subunit variant and essential hypertension in Japanese. Hypertension 32: 935-938
10. Kay S.R., Fiszbein A., Opler L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276
11. Lane H.Y., Chang Y.C., Chiu C.C., Chen M.L., Hsieh M.H., Chang W.H. (2002) Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 159: 1593-1595
12. Lane H.Y., Hsu S.K., Liu Y.C., Chang Y.C., Huang C.H., Chang W.H. (2005) Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 25: 6-11.
13. Lee B.H., Kim Y.K. (2006 b) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 30: 658-662
14. Lee B.H., Kim Y.K. (2006 a) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 30: 658-662
15. Lee H.J., Cha J.H., Ham B.J., Han C.S., Kim Y.K., Lee S.H., Ryu S.H., Kang R.H., Choi M.J., Lee M.S. (2004) Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 4: 29-33
16. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., Albert P.R. (2003) Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23: 8788-8799
17. Lerer B., Segman R.H. (2006) Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci 8: 85-94
18. Lesch K.P., Gutknecht L. (2005) Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 29: 1062-1073
19. Leysen J.E., Gommeren W., Eens A., de Chaffoy d C, Stoof J.C., Janssen P.A. (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661-670
20. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44: 1099-1117
21. Lucki I. (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44: 151-162
22. Markianos M., Hatzimanolis J., Lykouras L. (1999) Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology (Berl) 143: 270-272
23. Muller D.J., De L.V., Sicard T., King N., Hwang R., Volavka J., Czobor P., Sheitman B.B., Lindenmayer J.P., Citrome L., McEvoy J.P., Lieberman J.A., Meltzer H.Y., Kennedy J.L. (2005) Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 15: 525-531
24. Olesen O.V., Linnet K. (1997) Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl 698: 209-216
25. Reynolds G.P., Arranz B., Templeman L.A., Fertuzinhos S., San L. (2006) Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 163: 1826-1829
26. Reynolds G.P., Yao Z., Zhang X., Sun J., Zhang Z. (2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15: 143-151
27. Rothe C., Gutknecht L., Freitag C., Tauber R., Mossner R., Franke P., Fritze J., Wagner G., Peikert G., Wenda B., Sand P., Jacob C., Rietschel M., Nothen M.M., Garritsen H., Fimmers R., Deckert J., Lesch K.P. (2004) Association of a functional 1019C > G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 7: 189-192
28. Schunkert H., Hense H.W., Doring A., Riegger G.A., Siffert W. (1998) Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 32: 510-513
29. Siffert W., Forster P., Jockel K.H., Mvere D.A., Brinkmann B., Naber C., Crookes R., Du P.H., Epplen J.T., Fridey J., Freedman B.I., Muller N., Stolke D., Sharma A.M., Al Moutaery K., Grosse-Wilde H., Buerbaum B., Ehrlich T., Ahmad H.R., Horsthemke B., Du Toit E D., Tiilikainen A., Ge J., Wang Y., Rosskopf D. (1999) Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 10: 1921-1930
30. Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Sharma A.M., Ritz E., Wichmann H.E., Jakobs K.H., Horsthemke B. (1998). Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18: 45-48
31. Strobel A., Gutknecht L., Rothe C., Reif A., Mossner R., Zeng Y., Brocke B., Lesch K.P. (2003) Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. J Neural Transm 110: 1445-1453
32. Willeit M., Praschak-Rieder N., Zill P., Neumeister A., Ackenheil M., Kasper S., Bondy B. (2003) C825T polymorphism in the G protein beta3-subunit gene is associated with seasonal affective disorder. Biol Psychiatry 54: 682-686